These data demonstrate that miR-200a promotes the growth of osteosarcoma by impairing anti-tumor immunity in vivo, but at the same time, miR-200a OE group is also more sensitive to the treatment of anti-PD-L1 antibodies. The gene discussed is CD274; the disease is neoplasm.